Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

Hepatology

Volumn 27, Issue 4, 1998, Pages 1121-1127

  Farrell, Geoffrey C ^a   Bacon, Bruce R ^b   Goldin, Robert D ^c  

^a WESTMEAD HOSPITAL   (Australia)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHAN1 INTERFERON; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO; VIRUS TYPING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 0031923035     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270429     Document Type: Article

References (17)

1. Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. HEPATOLOGY 1990;12:671-675.
2. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-278.
3. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993;119:110-115.
4. Strasser SI, Watson KJR, Lee CS, Coghlan PJ, Desmond PV. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection. Med J Aust 1995;162:355-358.
5. Yano M, Kumada H, Kage M. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
6. Nishiguchi S, Kuroki T, Nakatani S. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
7. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
8. Davis GL, Balart LA, Schiff ER. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
9. Di Bisceglie AM, Martin P, Kassianides C. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
10. Lin R, Schoeman MN, Craig PI. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust N Z J Med 1991;21:387-392.
11. Marcellin P, Boyer N, Giostra E. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
12. Causse X, Godinot H, Chevallier M. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
13. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-199.
14. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon α-2b. A multicenter study. Dig Dis Sci 1993;38:612-8.
15. Benelux Multicentre Trial Study Group. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard vs high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993;(Suppl.):119S-120S.
16. Saracco G, Rosina F, Abate ML. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b. HEPATOLOGY 1993;18:1300-1305.
17. Poynard T, Bedossa P, Chevallier M. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-1462.